Roger is a highly experienced commercialisation and investment strategist with nearly 20 years of expertise in technology evaluation, spinouts, project management, capital raising, deal structuring, corporate strategy, and investment management. He has a deep understanding of health, life sciences, intellectual property management, and research translation, helping to bridge the gap between cutting-edge scientific discoveries and real-world healthcare solutions. Roger honed his skills in patents, licensing, and technology evaluation at the Swiss biopharmaceutical company Serono (later acquired by Merck). His academic background includes a PhD in biochemistry, post-doctoral research in immunology, and postgraduate studies in intellectual property law.

‍